Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etilevodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etilevodopa SCHEMBL7291700 | 1.00 | ALOX15 (0.62) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| Etilevodopa SCHEMBL29634876 | 0.98 | ALOX15 (0.64) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| Etilevodopa SCHEMBL1069939 | 0.98 | ALOX15 (0.64) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| Etilevodopa SCHEMBL584493 | 0.98 | ALOX15 (0.64) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| Etilevodopa SCHEMBL28278862 | 0.97 | ALOX15 (0.62) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| Etilevodopa SCHEMBL28209537 | 0.94 | ALOX15 (0.59) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| Etilevodopa SCHEMBL28067523 | 0.93 | ALOX15 (0.57) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| SCHEMBL6140024 | 0.87 | ALOX15 (0.60) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| SCHEMBL15679070 | 0.87 | ALOX15 (0.60) | ALOX15SLC7A5KDM4ERECQLHIF1A | |
| Melevodopa SCHEMBL453411 | 0.86 | ALOX15 (0.64) | ALOX15SLC7A5KDM4ERECQLHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030135065-A1 | Process for the production of L-DOPA ethyl ester | TEVA PHARMACEUTICAL INSDUSTRIES, LTD. (IL) | 2003-07-17 | — | — | US | claimed |
| WO-2003042136-A2 | PROCESS FOR THE PRODUCTION OF L-DOPA ETHYL ESTER | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-05-22 | — | — | WO | claimed |
| EP-1137626-A4 | PROCESS FOR MANUFACTURE OF L-DOPA ETHYL ESTER | TEVA PHARMA (IL) | 2002-07-17 | — | — | EP | claimed |
| US-20020026069-A1 | Process for manufacture of L-DOPA ethyl ester | LIDOR-HADAS RAMY (IL) | 2002-02-28 | — | — | US | claimed |
| EP-1137626-A1 | PROCESS FOR MANUFACTURE OF L-DOPA ETHYL ESTER | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-10-04 | — | — | EP | claimed |
| US-6218566-B1 | Process for manufacturing of L-DOPA ethyl ester | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2001-04-17 | — | — | US | claimed |
| WO-2000027801-A1 | PROCESS FOR MANUFACTURE OF L-DOPA ETHYL ESTER | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2000-05-18 | — | — | WO | claimed |
| US-11046640-B2 | Water-soluble L-DOPA esters | BERLIREM GMBH (DE) | 2021-06-29 | — | — | US | disclosed |
| EP-3277660-B1 | WATER-SOLUBLE L-DOPA ESTERS | BERLIREM GMBH (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-20190224153-A1 | L-DOPA DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | BERLIREM GMBH (DE) | 2019-07-25 | — | — | US | disclosed |
| US-20180362445-A1 | WATER-SOLUBLE L-DOPA ESTERS | BERLIREM GMBH (DE) | 2018-12-20 | — | — | US | disclosed |
| CN-104098860-B | The preparation method of Kynoar/poly-dopamine coated graphite alkene nanocomposite | 四川大学 | 2018-04-20 | — | — | CN | disclosed |
| EP-3277660-A1 | WATER-SOLUBLE L-DOPA ESTERS | Berlirem GmbH (DE) | 2018-02-07 | — | — | EP | disclosed |
| US-5354885-A | Esterifying L-DOPA with ethanol using an acid catalyst; diluting the devolatilized solution with water and antioxidant; adjusting pH; solvent extraction, precipitation and recrystallizing; Parkinson's disease | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-10-11 | — | — | US | disclosed |
| EP-0610595-A2 | Composition of l-dopa esters | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1994-08-17 | — | — | EP | disclosed |
| US-4873263-A | ESTER PRODRUG DERIVATIVES | MERCK & CO., INC. (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0287341-A1 | Rectally absorbable form of L-dopa | MERCK & CO. INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4771073-A | ESTER PRODRUG DERIVATIVES OF L-DOPA, OPTIONALLY WITH A DECARBOXYLASE INHIBITOR | MERCK & CO., INC. (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0228253-A1 | Rectally absorbable form of L-dopa | MERCK & CO. INC. (US) | 1987-07-08 | — | — | EP | disclosed |
| US-4663349-A | Rectally absorbable form of L-dopa | MERCK & CO., INC. (US) | 1987-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046640-B2 | Water-soluble L-DOPA esters | COMT, DDT, DDC | DRD3 253/4885ALOX15 153/4885SLC7A5 104/4885 |
| US-20190224153-A1 | L-DOPA DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | NLN, PARK7, COMT | DRD3 243/4885ALOX15 781/4885SLC7A5 198/4885 |
| US-20180362445-A1 | WATER-SOLUBLE L-DOPA ESTERS | COMT, DDT, DDC | DRD3 253/4885ALOX15 153/4885SLC7A5 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.